Diabetic foot, a devastating complication of long-term hyperglycemia, poses a severe threat to global health, affecting approximately 18% of diabetic patients worldwide . Its pathogenesis stems from dual impairments: peripheral neuropathy that dulls sensation, leaving feet vulnerable to unperceived injuries, and peripheral vascular disease that restricts blood flow, hindering wound healing . Without timely intervention, minor wounds can escalate into non-healing ulcers, infections, or gangrene, leading to amputations—with one diabetic foot patient losing a limb every 30 seconds globally .
The clinical spectrum of diabetic foot progresses through distinct stages, from asymptomatic high-risk feet with calluses or deformities to necrotic tissue requiring urgent intervention . Advanced cases demand multidisciplinary care, including minimally invasive vascular interventions like balloon angioplasty or stent placement, which have reduced major amputation rates by over 60% . For recurrent ulcers linked to bony prominences, minimally invasive osteotomy procedures offer effective offloading, achieving ulcer healing in an average of 9.8 weeks .
Innovations are transforming management beyond surgery. Wearable sensors and telemedicine enable remote monitoring of foot temperature and pressure, while advanced wound dressings and cell-based therapies accelerate healing of chronic ulcers . Prevention remains paramount: daily foot inspections, proper footwear, glycemic control (targeting fasting blood glucose ≤7.0mmol/L), and smoking cessation can reduce ulcer recurrence by 45-85% .
Addressing diabetic foot requires global collaboration to expand access to screening, train healthcare providers, and eliminate disparities—particularly for rural and low-income populations at higher risk . By integrating early detection, innovative treatments, and patient education, we can turn the tide against this preventable cause of disability and death.
